-
-
-
-
Manufacturing
-
Qilu King-Phar successfully passes the US FDA inspection with no 483 observations
ABOUT US
Qilu King-Phar successfully passes the US FDA inspection with no 483 observations
Release time：
2017-04-19
March 23, Qilu Pharmaceutical announces that its subsidiary King-Phar Pharmaceutical successfully has passed the US FDA inspection with no 483 observations for the third time.
Many aspects including material management, production management, quality management, laboratory management and packaging system are involved in this inspection and the performance of cGMP is highly praised by the auditor.
‘One millionth of the manufacturer is 100% of the patients’. Qilu Pharmaceutical has always been attaching great importance to the product quality and the quality system is strictly constructed to be geared to international standards. With the aim of exploring the international high-end markets, Qilu Pharmaceutical will continue adhering to the normalization for high standard of the production and quality management in the future,
Related News
0531-83126666 
wangzhan@qilu-pharma.com 
Tel: +86-531-83127705, 83127704, 83127706, 83127711
Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China
E mail：export@qilu-pharma.com, FDF@qilu-pharma.com